CHANGING THE WAY THE WORLD BREATHES · 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50% < 7 hrs sleep...

© RHINOMED LTD 2015 COMMERICAL IN CONFIDENCE WWW.RHINOMED.GLOBAL© RHINOMED LTD 2015 WWW.RHINOMED.GLOBAL

CHANGING THE WAY THE WORLD BREATHES

© RHINOMED LTD 2015 WWW.RHINOMED.GLOBAL

R H I N O M E D - N A S A L R E S P I R A T O R Y T E C H N O L O G Y

MAY 2016

For

per

sona

l use

onl

y


This document contains certain forward-looking statements, relating to Rhinomed Limited’s (Rhinomed) business which can be identified by the use of forward lookingterminology such as “promising”, “plans”, “anticipated” “will,” “project,” “believe,” “forecast”, “expected,” “estimated”, “targeting,” “aiming”, “set to”, “potential,” “seekingto”, “goal”, “could provide,” “intends”, “is being developed”, “could be,” “on track” or similar expressions or by express or implied discussions regarding potential filings ormarketing approvals, or potential future sales of the company’s technologies and products. Such forward-looking statements involve known and unknown risks, uncertaintiesand other factors that may causeactual results tobemateriallydifferent fromany future results, performanceor achievements expressed or implied bysuchstatements.

There can beno assurance that any existing or future regulatory filingswill satisfy any specific health authority and other health authorities requirements regarding any oneor moreproduct or technology nor can thereany assurance that such products or technologieswill beapproved by any health authorities for sale in anymarkets or that theywill reach any particular level of sales. In particular, managements expectations regarding theapproval and commercialization of the technology could beaffected by, amongother things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, orgovernment regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry,and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, technology, financial result, and businessprospects.

Should one of more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those describedherein as anticipated, believed, estimated or expected. Rhinomed Is providing this information as of the date of this presentation and does not assume any obligation toupdateany forward–looking statements contained in this document as a resultof new information, futureevents or developments orotherwise.

Disclaimer

For

per

sona

l use

onl

y


W H O I S R H I N O M E D ?

ASX:RNORespiratoryandbreathingmanagementtechnologycompany

CashonHand~ $4.0Million

Offices:Melbourne,AustraliaandCincinnati,USA Revenues:FYYTD – AU$750k

SharePrice~AU$0.023 Staff 11

MarketCap~AU$17million IP- 60+patents,13granted47 pending,plusanadditional57designpatents

Globallyexperiencedboardandmanagementteam

Mr RonDewhurst- Chairman Mr MichaelJohnson– CEOandManagingDirector

Mr Brent Scrimshaw- NonExecDirector Ms JustineHeath- CFO

Dr EricKnight- NonExecDirector Mr ShaneDuncan– VPGlobalSales

Mr PhillipHains – Company Secretary Ms Nairy Baghdikian – StrategicMarketingLeadFor

per

sona

l use

onl

y


Preclinical Phase 1 Regulatory In Market

TURBINE 2.0 OTC Dyspnea in Sport and Exercise

• FDA• TGA

• CANADA HEALTH• CE Mark

Preclinical User Trial

MUTE 1.0OTC Snoring and Sleep Quality

• FDA• TGA

• CANADA HEALTH• CE Mark

Congestion - OTC

Hayfever - OTC

Anxiety - OTC

Preclinical Phase 1 Phase 2 Phase 3 Regulatory In Market

Sleep Apnea

Drug Delivery – Acute Migraine (sumatriptan)

Seeking to partner

A N O V E L N A S A L T E C H N O L O G Y P L A T F O R M

© RHINOMED LTD 2015

For

per

sona

l use

onl

y


R H I N O M E D I S P U R S U I N G A S I G N I F I C A N T G L O B A L O P P O R T U N I T Y

• Rhinomed isamplifying thebeliefthatbetterbreathingcanradicallyimprovehowyouperform,

recover,sleepandmaintainyourhealthbycreatingtheworld’smostelegant,innovativeand

clinicallybackednasalrespiratorytechnology.

• Wepartnerwiththeworld’sbestandbrightestpeople tomakethisareality.

For

per

sona

l use

onl

y


• TheUnitedStatesCentersforDiseaseControlandPreventionhasdeclaredsleepdeprivationa

nationalepidemic.

• AntisnoringmarketexpectedtogrowfromUS$744in2015toUS$1.232Billion in2020

• GrowingatCAGRof10.6%perannum

0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50%

<7hrs sleep

Snorers

35%

48%

AmericanPopulation

P O O R S L E E P I S A G L O B A L H E A L T H E P I D E M I C

Source:CentreForDiseaseControlandPrevention.

For

per

sona

l use

onl

y


S L E E P I S N O W A M A J O R C O N S U M E R H E A L T H T H E M E

Appleincludedanew‘bluelightfunction intheirnewiphone OSreleaseinMarch‘16

HuffingtonPostfounderAriannaHuffingtonistakingtheUSbystorm

Sleepisbeingpickedupmainstreammediaasa‘healthstory’

For

per

sona

l use

onl

y


T H E S L E E P C A T E G O R Y R E P R E S E N T S A M A J O R C O M M E R C I A L O P P O R T U N I T Y

Snorerscan’tfindaneffectiveOTC

solution:

• 73%ofnasalsprayusersfindthem

ineffective

• 81%ofthroatsprayusersfindthem

ineffective

• 75%ofnasalstripusersfindthem

ineffective

• therehasbeenalackofmedically

backedinnovation

• valueformoneyhasbeenpoor

Consumersratepopular snoringsolutions

For

per

sona

l use

onl

y


M U T E - C L I N I C A L L Y B A C K E D I N N O V A T I O N

• Acomfortable,scientificallyproven,disposablenasalstentthatimprovesairflowandreducessnoring• Adjustableforeachnostriltoensureultimatecomfortandfit• Eachpackcontains3Mutes

• Availableinatrialpack(contains3differentsizes)andthreesizes(small,medium&large)• Reusableupto10times,thussmall,medium&largepacklasts30days

For

per

sona

l use

onl

y


M U T E O U T P E R F O R M S B R E A T H E R I G H T S T R I P S

Rhinomed’s technologyhasbeenshownina2003clinicaltrialtooutperformthe

BreatheRightStripbyanaverageof38%Source:BrahamS,Varigos J.RoyalVictorianEyeandEarHospitalPhase1,"ProofofPrinciple",n=20Randomised, Cross-OverStudyoftheEffectof ANewTherapeutic

DeviceandaMarketedDeviceonNasalAirflowRatesinNormal,HealthyAdults2003

Rhinomed’s technologyhasbeenshownina2014fiveday,inhome,usertrialtoreducesnoring.

Source:Baghdikian N,Cogentum.Effect ofMuteNasalstentonSnoringandSleepQuality.n=236.FiveDayin-homeusertrial,bedpartneranduserreporting2014

For

per

sona

l use

onl

y


SPECIALISTS

GP’S

SLEEPCLINICS

DENTISTS

HOSPITALS

ONLINE

RETAILCHANNEL

ENTSURGEONS

GLOBAL RETAIL PHARMACY

CHANNEL DEPLOYMENT

D I S T R I B U T E D G L O B A L L Y T H R O U G H A M U L T I C H A N N E L S T R A T E G Y

For

per

sona

l use

onl

y


S T R O N G R E T A I L S T O R E G R O W T H I N K E Y M A R K E T S

• LaunchedMuteinFeb2015

• 2000+storeslivetoday(plusstrong

pipeline)

• Footprint inAustralia,UK,Canada

andUSA

For

per

sona

l use

onl

y


U N I Q U E , C U T T H R O U G H B R A N D

For

per

sona

l use

onl

y


C U S T O M E R S L O V E M U T E

For

per

sona

l use

onl

y


T U R B I N E – S P O R T S B R E A T H I N G T E C H N O L O G Y

• TURBINE2.0- ReleasedFeb2015

• Designedtohelpathletesbreatheeasierduringsportandaerobicexerciseandhelpsthose sufferingfromnasal

obstruction

• Nowdistributedglobally

• Availableinthreesizesandatrialpack

• RRPAU$29.95deliveringstrongmargins


For

per

sona

l use

onl

y


TurbinehelpedChrisFroome winhissecondTourdeFrance

For

per

sona

l use

onl

y


TurbinehelpedShannonRowbury setanewAmericanrecordforthe1500meters

For

per

sona

l use

onl

y


InthelastyearTurbinehashelpedpeopleallovertheworldachievenewrecordsandsetnew‘personalbests’bymakingeverybreathcount.

C U S T O M E R S L O V E T U R B I N E

For

per

sona

l use

onl

y


I N N O V A T I O N P I P E L I N E

For

per

sona

l use

onl

y


E N D T O E N D S L E E P C A T E G O R Y S O L U T I O N S

SNORING

ON MARKET

CU

STO

MER

PAT

IEN

T NU

MBE

R

MUTE 'CLEAR'Aroma enhanced

(menthol, eucalypt, sleep & relaxation

blends)

NASAL CONGESTION

MILD/MODERATE SLEEP APNEA

SEVERESLEEP APNEA

NAS

AL P

LATF

ORM

RNO INPEAPClinical trials (Reporting

first half 2016)

RNO ASPIRECombination Adjunct

Therapy

RNO + CPAP MaskRNO + Mandibular Splint


For

per

sona

l use

onl

y


N E X T G E N E R A T I O N N A S A L D E C O N G E S T A N T


For

per

sona

l use

onl

y


U S $ 8 B I L L I O N D E C O N G E S T I O N M A R K E T

MUTE‘CLEAR’• Nextgenerationmultiformulation

platform• Overnightnasaldecongestant• Class1product– regulatoryprocess

commencing• Designbeingfinalisedandproduction

scopingunderway• TARGETRELEASE– DECEMBER2016

MUTE• Inmarket• Resolvessnoring• Improvessleepquality• Adjunct toexistingsleeptherapies

For

per

sona

l use

onl

y


S L E E P A P N E A – U S $ 3 2 B I L L I O N O P P O R T U N I T Y

For

per

sona

l use

onl

y


W I T H A B I L L I O N D O L L A R P R O B L E M

For

per

sona

l use

onl

y


© RHINOMED LTD 2015 COMMERICAL IN CONFIDENCE

M U T E - A N A D J U N C T T O E X I S T I N G S L E E P A P N E A T H E R A P I E S

• Proofofcomplianceisincreasinglyrequiredbyinsurersbeforereimbursement

• Rhinomednasalstentlowersnasalresistance– opens upupperairway

• IncreasinglyrecommendedbySleepSpecialists,SleepTechniciansandDentistsasanadjunct

therapytoMandibularAdvancementDevicesandLowAHIPatientstoresolvecomplianceissues

• Rhinomedisworkingcloselywithsleepspecialiststobeginscopingatrial

LocationofanteriorcoronalsliceLocationofposterior

coronalslice

For

per

sona

l use

onl

y


I N P E A P – A N E W F R O N T L I N E S L E E P A P N E A T H E R A P Y

• PatentedINPEAPtechnology• Targeting70%ofOSApatientswith

moderateOSA(AHI14-29)• Lowinvasive• Welltolerated• Nasalstentingcoupledwithnasally

deliveredEPAP• TrialunderwayatMonash LungandSleep

Dept.Monash Health

IntranasalPositiveExpiratoryAirwayPressure(INPEAP)


For

per

sona

l use

onl

y


S U M M A R Y

• Compelling technology inagrowingglobalmarket

• Businessisrapidlyexpanding revenuebasethrough globaldistribution footprint

• Keyfocusisexpansion in:

• USAandCanada

• UK

• Aust/NZbase

• NearTermnewflow– moredistribution agreements,SleepApneaTrialresultsexpected

• Cashonhand~AU$4.0million

• Compelling investmentcomparator– BreatheRightStrips– purchasedbyGSK- US$566min2007

For

per

sona

l use

onl

y


MICHAEL JOHNSON, CEOe. [email protected]

t. +61 3 8416 0900w. rhinomed.global

For

per

sona

l use

onl

y

Date post:	10-Jul-2020
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times

CHANGING THE WAY THE WORLD BREATHES · 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50% < 7 hrs sleep...

Documents